BG61665B2 - Вододиспергируеми таблетки - Google Patents

Вододиспергируеми таблетки Download PDF

Info

Publication number: BG61665B2
Authority: BG; Bulgaria
Prior art keywords: tablet; acyclovir; tablet according; tablets; granules
Prior art date: 1991-01-30

Application number

BG098071A

Other languages

Bulgarian (bg)

English (en)

Inventor

Krystyna FIELDEN

Original Assignee

The Wellcome Foundation Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-30

Filing date

1993-08-26

Publication date

1998-02-27

1991-01-30 Priority claimed from GB919102019A external-priority patent/GB9102019D0/en

1991-11-22 Priority claimed from GB919124803A external-priority patent/GB9124803D0/en

1991-11-22 Priority claimed from GB919124807A external-priority patent/GB9124807D0/en

1991-11-25 Priority claimed from GB919125005A external-priority patent/GB9125005D0/en

1993-08-26 Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited

1998-02-27 Publication of BG61665B2 publication Critical patent/BG61665B2/bg

Links

XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 29
239000004927 clay Substances 0.000 claims abstract description 56
150000003839 salts Chemical class 0.000 claims abstract description 14
238000012360 testing method Methods 0.000 claims abstract description 13
239000003826 tablet Substances 0.000 claims description 160
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 68
229960004150 aciclovir Drugs 0.000 claims description 68
239000008187 granular material Substances 0.000 claims description 56
239000006185 dispersion Substances 0.000 claims description 44
230000008961 swelling Effects 0.000 claims description 36
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 27
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 26
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 25
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 24
238000000034 method Methods 0.000 claims description 20
229940069328 povidone Drugs 0.000 claims description 20
238000005469 granulation Methods 0.000 claims description 19
230000003179 granulation Effects 0.000 claims description 19
239000003795 chemical substances by application Substances 0.000 claims description 17
239000002245 particle Substances 0.000 claims description 16
239000004565 water dispersible tablet Substances 0.000 claims description 16
229920002472 Starch Polymers 0.000 claims description 15
239000011230 binding agent Substances 0.000 claims description 15
229940032147 starch Drugs 0.000 claims description 15
239000008107 starch Substances 0.000 claims description 15
235000019698 starch Nutrition 0.000 claims description 15
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 14
239000007919 dispersible tablet Substances 0.000 claims description 14
235000019359 magnesium stearate Nutrition 0.000 claims description 14
239000000440 bentonite Substances 0.000 claims description 12
229910000278 bentonite Inorganic materials 0.000 claims description 12
239000000546 pharmaceutical excipient Substances 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 12
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 11
150000001875 compounds Chemical class 0.000 claims description 10
239000000945 filler Substances 0.000 claims description 10
238000002156 mixing Methods 0.000 claims description 10
229910021647 smectite Inorganic materials 0.000 claims description 10
229920003109 sodium starch glycolate Polymers 0.000 claims description 10
239000008109 sodium starch glycolate Substances 0.000 claims description 10
229940079832 sodium starch glycolate Drugs 0.000 claims description 10
238000009826 distribution Methods 0.000 claims description 8
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
239000000314 lubricant Substances 0.000 claims description 7
239000008108 microcrystalline cellulose Substances 0.000 claims description 7
229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 6
238000001035 drying Methods 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
239000007888 film coating Substances 0.000 claims description 5
238000009501 film coating Methods 0.000 claims description 5
229910052901 montmorillonite Inorganic materials 0.000 claims description 5
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
239000004353 Polyethylene glycol 8000 Substances 0.000 claims description 4
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
229940085678 polyethylene glycol 8000 Drugs 0.000 claims description 4
235000019446 polyethylene glycol 8000 Nutrition 0.000 claims description 4
229940009868 aluminum magnesium silicate Drugs 0.000 claims description 3
WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 3
239000000796 flavoring agent Substances 0.000 claims description 3
239000012530 fluid Substances 0.000 claims description 3
235000013355 food flavoring agent Nutrition 0.000 claims description 3
229910000271 hectorite Inorganic materials 0.000 claims description 3
KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 claims description 3
229910052902 vermiculite Inorganic materials 0.000 claims description 3
239000010455 vermiculite Substances 0.000 claims description 3
235000019354 vermiculite Nutrition 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 2
229910000276 sauconite Inorganic materials 0.000 claims description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
239000011777 magnesium Substances 0.000 description 8
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
229920003081 Povidone K 30 Polymers 0.000 description 7
239000002202 Polyethylene glycol Substances 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
230000009747 swallowing Effects 0.000 description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
229940079593 drug Drugs 0.000 description 5
229910052500 inorganic mineral Inorganic materials 0.000 description 5
-1 magnesium aluminum silicates Chemical class 0.000 description 5
239000011707 mineral Substances 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 4
239000002734 clay mineral Substances 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
229910052749 magnesium Inorganic materials 0.000 description 4
239000000463 material Substances 0.000 description 4
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
208000007514 Herpes zoster Diseases 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
229920001429 chelating resin Polymers 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000008119 colloidal silica Substances 0.000 description 3
238000007906 compression Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000011229 interlayer Substances 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000010445 mica Substances 0.000 description 3
229910052618 mica group Inorganic materials 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001026509 Kata Species 0.000 description 2
229920003085 Kollidon® CL Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
229920003110 Primojel Polymers 0.000 description 2
239000004113 Sepiolite Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
230000001055 chewing effect Effects 0.000 description 2
230000006835 compression Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
230000037406 food intake Effects 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
230000001788 irregular Effects 0.000 description 2
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229910052624 sepiolite Inorganic materials 0.000 description 2
235000019355 sepiolite Nutrition 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
239000000811 xylitol Substances 0.000 description 2
235000010447 xylitol Nutrition 0.000 description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
229960002675 xylitol Drugs 0.000 description 2
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
240000000560 Citrus x paradisi Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
235000016623 Fragaria vesca Nutrition 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
235000011363 Fragaria x ananassa Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
208000001688 Herpes Genitalis Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
244000288157 Passiflora edulis Species 0.000 description 1
235000000370 Passiflora edulis Nutrition 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
244000235659 Rubus idaeus Species 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
239000004990 Smectic liquid crystal Substances 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229910001583 allophane Inorganic materials 0.000 description 1
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Polymers [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
JLQUFIHWVLZVTJ-UHFFFAOYSA-N carbosulfan Chemical compound CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 JLQUFIHWVLZVTJ-UHFFFAOYSA-N 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000012461 cellulose resin Substances 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
229910001919 chlorite Inorganic materials 0.000 description 1
229910052619 chlorite group Inorganic materials 0.000 description 1
QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229940065410 feldene Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229910021485 fumed silica Inorganic materials 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
201000004946 genital herpes Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229910052622 kaolinite Inorganic materials 0.000 description 1
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
229960001848 lamotrigine Drugs 0.000 description 1
229940094522 laponite Drugs 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Polymers CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000003921 particle size analysis Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229910052615 phyllosilicate Inorganic materials 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
238000005498 polishing Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Polymers [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
229910052903 pyrophyllite Inorganic materials 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
229940085605 saccharin sodium Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229910000275 saponite Inorganic materials 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000011555 saturated liquid Substances 0.000 description 1
229910000269 smectite group Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Polymers [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
AYGJDUHQRFKLBG-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;dihydrate Chemical compound O.O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 AYGJDUHQRFKLBG-UHFFFAOYSA-M 0.000 description 1
239000002689 soil Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
229910001771 thuringite Inorganic materials 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
AZJYLVAUMGUUBL-UHFFFAOYSA-A u1qj22mc8e Chemical compound [F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O=[Si]=O.O=[Si]=O.O=[Si]=O.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 AZJYLVAUMGUUBL-UHFFFAOYSA-A 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
General Preparation And Processing Of Foods (AREA)
Cosmetics (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Glanulating (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BG098071A 1991-01-30 1993-08-26 Вододиспергируеми таблетки BG61665B2 (bg)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB919102019A GB9102019D0 (en)	1991-01-30	1991-01-30	Pharmaceutical formulations
GB919124803A GB9124803D0 (en)	1991-11-22	1991-11-22	Pharmaceutical formulations
GB919124807A GB9124807D0 (en)	1991-11-22	1991-11-22	Pharmaceutical formulations
GB919125005A GB9125005D0 (en)	1991-11-25	1991-11-25	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
BG61665B2 true BG61665B2 (bg)	1998-02-27

Family

ID=27450613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG098071A BG61665B2 (bg)	1991-01-30	1993-08-26	Вододиспергируеми таблетки

Country Status (37)

Country	Link
US (2)	US5556639A (ru)
EP (1)	EP0522128B1 (ru)
JP (2)	JP3118255B2 (ru)
KR (1)	KR100190254B1 (ru)
AT (1)	ATE133068T1 (ru)
AU (2)	AU653203B2 (ru)
BE (1)	BE1004461A5 (ru)
BG (1)	BG61665B2 (ru)
CA (1)	CA2098108C (ru)
CH (1)	CH685978A5 (ru)
CY (1)	CY2007A (ru)
CZ (1)	CZ286723B6 (ru)
DE (2)	DE4290300T1 (ru)
DK (2)	DK0522128T3 (ru)
ES (2)	ES2089498T3 (ru)
FI (2)	FI111605B (ru)
FR (1)	FR2671970B1 (ru)
GB (1)	GB2257363B (ru)
GR (1)	GR3019545T3 (ru)
HK (1)	HK78597A (ru)
HU (2)	HU221677B1 (ru)
IE (1)	IE77165B1 (ru)
IL (1)	IL100796A (ru)
IT (1)	IT1257473B (ru)
LU (1)	LU88323A1 (ru)
MX (1)	MX9200412A (ru)
MY (2)	MY110880A (ru)
NL (1)	NL9220009A (ru)
NO (1)	NO306697B1 (ru)
PA (1)	PA7695401A1 (ru)
PL (1)	PL169106B1 (ru)
RU (1)	RU2106861C1 (ru)
SA (1)	SA92120365B1 (ru)
SE (1)	SE9302363D0 (ru)
SK (2)	SK282071B6 (ru)
UA (1)	UA37214C2 (ru)
WO (1)	WO1992013527A1 (ru)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9424766D0 (en) *	1994-12-07	1995-02-08	Wellcome Found	Pharmaceutical composition
ES2079327B1 (es) *	1994-12-13	1996-08-01	Lilly Sa	Formulaciones farmaceuticas de cefaclor.
GB9501127D0 (en) *	1995-01-20	1995-03-08	Wellcome Found	Tablet
GB9518465D0 (en) *	1995-09-09	1995-11-08	Smithkline Beecham Seiyaku Kk	Pharmaceuticals
GB9600847D0 (en) *	1996-01-16	1996-03-20	Smithkline Beecham Plc	Pharmaceuticals
FR2759706B1 (fr) *	1997-02-18	2003-11-28	Alain Perrier	Procede de traitement de l'argile a des fins therapeutiques et produits obtenus par ce procede
US6129932A (en) *	1997-09-05	2000-10-10	Merck & Co., Inc.	Compositions for inhibiting platelet aggregation
US5955107A (en) *	1997-12-12	1999-09-21	Fmc Corporation	Pharmaceutical suspension tablet compositions
DE19820801A1 (de) *	1998-05-09	1999-11-25	Gruenenthal Gmbh	Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
EP1135118A1 (en)	1998-11-10	2001-09-26	Teva Pharmaceutical Industries Ltd.	Dispersible compositions containing l-dopa ethyl ester
PE20001302A1 (es) *	1998-11-27	2000-11-30	Hoffmann La Roche	Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
EP1161940B1 (en) *	1999-02-17	2005-06-08	Kyowa Hakko Kogyo Co., Ltd.	Tablets and process for producing tablets
US6399591B1 (en) *	2000-01-19	2002-06-04	Yung-Shin Pharmaceutical Ind. Co., Ltd.	Chargeable pharmaceutical tablets
GB0010446D0 (en) *	2000-04-28	2000-06-14	Glaxo Wellcome Kk	Pharmaceutical formulation
US6555145B1 (en) *	2000-06-06	2003-04-29	Capricorn Pharma, Inc.	Alternate encapsulation process and products produced therefrom
US6365209B2 (en) *	2000-06-06	2002-04-02	Capricorn Pharma, Inc.	Confectionery compositions and methods of making
US6358526B1 (en)	2000-08-16	2002-03-19	Rexall Sundown	Method of making tablets and tablet compositions produced therefrom
EA005497B1 (ru) *	2001-01-03	2005-02-24	Берлин Хеми Аг	Применение фармацевтической композиции, содержащей бривудин, для лечения герпесвирусных инфекций
US7939102B2 (en) *	2002-06-07	2011-05-10	Torrent Pharmaceuticals Ltd.	Controlled release formulation of lamotrigine
US8637512B2 (en)	2002-07-29	2014-01-28	Glaxo Group Limited	Formulations and method of treatment
GB0223978D0 (en) *	2002-10-15	2002-11-20	Novartis Ag	Organic compound
US8992980B2 (en)	2002-10-25	2015-03-31	Boehringer Ingelheim Vetmedica Gmbh	Water-soluble meloxicam granules
US20040109889A1 (en) *	2002-12-04	2004-06-10	Bunick Frank J.	Surface treatment composition for soft substrates
EP1608342A2 (en) *	2003-03-21	2005-12-28	Ranbaxy Laboratories, Ltd.	Stable lamotrigine pharmaceutical compositions and processes for their preparation
US7282217B1 (en)	2003-08-29	2007-10-16	Kv Pharmaceutical Company	Rapidly disintegrable tablets
US20070116764A1 (en)	2003-12-01	2007-05-24	Shigeyuki Marunaka	Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing
US8309103B2 (en) *	2004-01-22	2012-11-13	Alparis, S.A. De C.V.	Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage
EP1568369A1 (en)	2004-02-23	2005-08-31	Boehringer Ingelheim Vetmedica Gmbh	Use of meloxicam for the treatment of respiratory diseases in pigs
US20050244493A1 (en) *	2004-04-30	2005-11-03	Withiam Michael C	Rapidly disintegrating tablets comprising calcium carbonate
US20050244347A1 (en) *	2004-04-30	2005-11-03	Mehra Dev K	Oral care products comprising calcium phosphates
US20070196477A1 (en) *	2004-04-30	2007-08-23	Withiam Michael C	Rapidly dissolving tablets comprising low surface area calcium phosphates
CN100340235C (zh) *	2004-05-21	2007-10-03	山东绿叶制药有限公司	蒙脱石分散片及其制备工艺
US20060008492A1 (en) *	2004-07-09	2006-01-12	Pablo Janowicz	Composition and method for delivering chemical agent to insects
DE102004042139B4 (de) *	2004-08-31	2009-06-10	Aristocon Verwaltungs- Gmbh	Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
NZ560232A (en) *	2005-02-25	2010-11-26	Hoffmann La Roche	Tablets with improved drug substance dispersibility
IS7724A (is) *	2005-03-02	2006-09-03	Actavis Group	Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat
RS20070512A (en) *	2005-06-29	2009-01-22	Panacea Biotec Ltd.,	Pharmaceutical sustained release compositionsand processes thereof
EP1906937B1 (en)	2005-07-22	2016-10-19	Rubicon Research Pvt Ltd.	Novel dispersible tablet composition
NZ567627A (en) *	2005-09-30	2011-08-26	Boehringer Ingelheim Vetmed	Granulation process for making a divisible tablet containing meloxicam
FR2912059B1 (fr) *	2007-02-06	2013-04-05	Scras	Utilisation d'argiles pour le traitement de la maladie coeliaque
WO2008104996A2 (en) *	2007-02-28	2008-09-04	Jubilant Organosys Limited	Water dispersible pharmaceutical formulation and process for preparing the same
GB0708929D0 (en) *	2007-05-09	2007-06-20	Glaxosmithkline Consumer Healt	Composition
GB0709541D0 (en) *	2007-05-17	2007-06-27	Jagotec Ag	Pharmaceutical excipient
TWI547282B (zh)	2007-07-02	2016-09-01	愛戴爾製藥股份有限公司	樂命達之口服分解錠劑組合物
US20090022789A1 (en) *	2007-07-18	2009-01-22	Supernus Pharmaceuticals, Inc.	Enhanced formulations of lamotrigine
WO2009063484A2 (en) *	2007-08-03	2009-05-22	Alkem Laboratories Ltd	Stable pharmaceutical composition of lamotrigine
EP2100595A1 (en) *	2008-03-10	2009-09-16	The Procter and Gamble Company	Compressed tablets
CN102105140B (zh) *	2008-07-02	2013-10-23	巴斯夫欧洲公司	涂覆片剂的方法
EP2612681B1 (en) *	2010-08-31	2019-01-30	Toray Industries, Inc.	Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation
USD666096S1 (en)	2010-11-01	2012-08-28	Colgate-Palmolive Company	Cap for a container
USD666099S1 (en)	2010-11-01	2012-08-28	Colgate-Palmolive Company	Cap for a container
USD666098S1 (en)	2010-11-01	2012-08-28	Colgate-Palmolive Company	Cap for a container
USD666097S1 (en)	2010-11-01	2012-08-28	Colgate-Palmolive Company	Cap for a container
USD666493S1 (en)	2010-11-01	2012-09-04	Colgate-Palmolive Company	Cap for a container
USD666492S1 (en)	2010-11-01	2012-09-04	Colgate-Palmolive Company	Cap for a container
RU2462243C1 (ru) *	2011-08-17	2012-09-27	Вемур Инвестментс Лимитед	Средство для снятия похмельного синдрома
RU2558091C2 (ru) *	2013-07-04	2015-07-27	Общество с ограниченной ответственностью "Трейдсервис"	Диспергируемая таблетка смектита диоктаэдрического и способ ее получения
WO2018071547A1 (en) *	2016-10-11	2018-04-19	Aucta Pharmaceuticals	Powder for oral suspension containing lamotrigine
CN107115304B (zh) *	2017-04-10	2019-02-26	浙江寿仙谷医药股份有限公司	一种去壁灵芝孢子粉片剂及其制备方法
KR102704497B1 (ko) *	2017-12-08	2024-09-10	에프. 호프만-라 로슈 아게	약학 제형

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB777516A (en) *	1955-04-14	1957-06-26	Griffiths Hughes Ltd E	Improvements in or relating to the production of tablets by pressure
GB837451A (en) *	1956-02-20	1960-06-15	Arner Co Inc	Sustained release therapeutic composition and process of preparing same
US3432593A (en) *	1963-09-18	1969-03-11	Key Pharm Inc	Delayed and sustained release type pharmaceutical preparation
US3427379A (en) *	1966-01-13	1969-02-11	Hoffmann La Roche	Dextromethorphan and benzyl alcohol hard candy lozenges free from opaqueness and/or tiny entrapped air bubbles
US3567819A (en) *	1969-01-30	1971-03-02	Hoffmann La Roche	Cold tablet
DE2016622A1 (en) *	1970-04-08	1971-10-21	Farbenfabriken Bayer Ag, 5090 Leverkusen	Anthelmintic benzimidazole deriv
CA926708A (en) *	1970-06-15	1973-05-22	Oushima Yoshitaka	Process for producing spherical pellets
US4072535A (en) *	1970-12-28	1978-02-07	A. E. Staley Manufacturing Company	Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2183546B1 (ru) *	1972-05-10	1975-06-20	Servier Lab
DE2251249A1 (de) *	1972-10-19	1974-05-02	Hoechst Ag	Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten
US4209513A (en) *	1974-02-14	1980-06-24	Burroughs Wellcome Co.	Tablet formulation
DE2416903A1 (de) *	1974-04-06	1975-10-09	Bayer Ag	Verwendung von schmelzverspruehtem kugelfoermigem phenacetingranulat zur herstellung von tabletten im direkttablettierverfahren
JPS5154918A (en) *	1974-10-08	1976-05-14	Nippon Kayaku Kk	Jozaino seizoho
GB1533243A (en) *	1975-02-13	1978-11-22	Wellcome Found	Tablet formulation
CH630257A5 (en) *	1975-03-17	1982-06-15	Hoffmann La Roche	Sustained release formulation
US4086335A (en) *	1975-10-29	1978-04-25	Bruscato Frank N	Pharmaceutical tablets containing chitin as a disintegrant
GB1548022A (en) *	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
GB1567392A (en) *	1977-02-22	1980-05-14	Farmaceutici Italia	Daunorubicin derivatives
AU508480B2 (en) *	1977-04-13	1980-03-20	Asahi Kasei Kogyo Kabushiki Kaisha	Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
CA1097233A (en) *	1977-07-20	1981-03-10	George K. E. Gregory	Packages
GB1601833A (en) *	1978-02-06	1981-11-04	Wellcome Found	Antacid formulation
JPS54129129A (en) *	1978-03-30	1979-10-06	Sankyo Co Ltd	Powdered pesticide having suppressed static electrification
DE2845326C2 (de) *	1978-10-18	1985-05-23	Beiersdorf Ag, 2000 Hamburg	Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
DE2849494A1 (de) *	1978-11-15	1980-05-29	Voss Gunter M	Verfahren zur herstellung von arzneimittel-formlingen
CA1112643A (en) *	1979-06-01	1981-11-17	Martin G. Baxter	3,5-diamino-6-phenyl-1,2,4-triazines
US4251518A (en) *	1979-07-03	1981-02-17	Ralston Purina Company	Method of preparing readily disintegrable pharmaceutical compositions
JPS56127309A (en) *	1980-03-11	1981-10-06	Dai Ichi Seiyaku Co Ltd	Zeolite support for ascorbic acid
JPS5711913A (en) *	1980-06-24	1982-01-21	Tsumura Juntendo Inc	Preparation of hard-capsule of herb medicine
JPS5711911A (en) *	1980-06-25	1982-01-21	Tsumura Juntendo Inc	Preparation of herb medicine tablet
US4304773A (en) *	1980-06-26	1981-12-08	E. R. Squibb & Sons, Inc.	Novel bendroflumethiazide formulations and method
JPS5756434A (en) *	1980-09-22	1982-04-05	Kao Corp	Stabilized foamable composition
ATE13486T1 (de) *	1980-11-12	1985-06-15	Ciba Geigy Ag	Schnellzerfallende arzneimittel-presslinge.
US4369308A (en) *	1981-07-24	1983-01-18	National Starch And Chemical Corporation	Low swelling starches as tablet disintegrants
HU189534B (en) *	1981-09-09	1986-07-28	Chinoin Rt.,Hu	Process for producing new tablets containing cyclodextrin polymer as desintegrator
US4414198A (en) *	1982-04-23	1983-11-08	Joseph Michaelson	Rapidly disintegrable tablet composition and method
GB2119355B (en) *	1982-04-29	1985-05-09	Scras	Modified clays
IL68311A0 (en) *	1982-04-29	1983-07-31	Scras	Modified clays,their preparation and pharmaceutical compositions containing them
GR79340B (ru) *	1982-07-06	1984-10-22	Sterwin Ag
US4517179A (en) *	1983-04-29	1985-05-14	Pennwalt Corporation	Rapid dissolving, uniform drug compositions and their preparation
US4600579A (en) *	1983-06-07	1986-07-15	Mallinckrodt, Inc.	N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
CH658188A5 (de) *	1984-03-23	1986-10-31	Ciba Geigy Ag	Lagerstabile schnellzerfallende pharmazeutische presslinge.
US4661521A (en) *	1984-04-30	1987-04-28	Mallinckrodt, Inc.	Direct tableting acetaminophen compositions
DE3505433A1 (de) *	1985-02-16	1986-08-21	Basf Ag, 6700 Ludwigshafen	Direkttablettierhilfsmittel
US4631305A (en) *	1985-03-22	1986-12-23	The Upjohn Company	Polymeric material as a disintegrant in a compressed tablet
EP0199855A1 (en) *	1985-05-02	1986-11-05	Gist-Brocades N.V.	Tablets comprising tromethoprim and a sulfonamide
EP0272265B1 (de) *	1985-09-25	1991-05-22	Gergely, Gerhard, Dr.	Zerfallstablette und verfahren zu ihrer herstellung
US4781925A (en) *	1986-03-06	1988-11-01	American Home Products Corporation	Calcium supplement compressed tablets
JPS62227729A (ja) *	1986-03-31	1987-10-06	Kanegafuchi Chem Ind Co Ltd	断熱材
JPH01501934A (ja) *	1986-04-01	1989-07-06	ジ・アップジョン・カンパニー	メチルプレドニソロン／カルボキシメチルスターチナトリウム錠剤組成物
GB8613183D0 (en) *	1986-05-30	1986-07-02	Wellcome Found	Triazine salt
DE3635864A1 (de) *	1986-06-26	1988-05-05	Gerhard Gergely	Verfahren zum herstellen eines brausegranulates, danach hergestelltes brausegranulat sowie dessen verwendung
US4757090A (en) *	1986-07-14	1988-07-12	Mallinckrodt, Inc.	Direct tableting acetaminophen compositions
KR960001372B1 (ko) *	1986-09-24	1996-01-26	예일 유니버시티	레트로비루스로 감염된 환자의 치료에 사용되는 2',3'-디디옥시사이티딘-2'-엔(2',3'-디디옥시-2',3'-디디하이드로사이티딘)의 항생물질
GB8624628D0 (en) *	1986-10-14	1986-11-19	Scras	Soluble/splitable tablets
US4771077A (en) *	1986-10-21	1988-09-13	American Home Products Corporation (Del.)	Spray dried acetaminophen
GB8628359D0 (en) *	1986-11-27	1986-12-31	Zyma Sa	Galenical formulation
DE3887179T2 (de) *	1987-03-02	1994-06-16	Brocades Pharma Bv	Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
EP0294933B1 (en) *	1987-05-08	1992-03-11	Smith Kline & French Laboratories Limited	Pharmaceutical compositions
US4904477A (en) *	1987-07-08	1990-02-27	American Home Products Corporation	Spray dried ibuprofen compositions
ES2026198T3 (es) *	1987-07-22	1992-04-16	Farvalsa Ag	Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion.
JP2527973B2 (ja) *	1987-08-05	1996-08-28	株式会社資生堂	球状粘土鉱物及びその製造方法
DE3806633A1 (de) *	1987-09-01	1989-03-09	Bayer Ag	Antivirales mittel
US4837031A (en) *	1987-09-17	1989-06-06	Mallinckrodt, Inc.	Compositions containing ibuprofen
JP2537062B2 (ja) *	1987-10-02	1996-09-25	株式会社資生堂	薬剤組成物
US4999200A (en) *	1987-12-09	1991-03-12	Marion Laboratories	Psyllium tablet composition, method of manufacture and method of use
ATE108996T1 (de) *	1988-02-25	1994-08-15	Brocades Pharma Bv	Verfahren zur herstellung eines pharmazeutischen granulats.
US4910023A (en) *	1988-06-09	1990-03-20	Warner-Lambert Company	Drug in combination with flavor masking agent and method for making same
YU120988A (en) *	1988-06-23	1990-06-30	Lek Tovarna Farmacevtskih	Process for preparing new dispersion pills of cimetidine
IT1226549B (it) *	1988-07-12	1991-01-24	Resa Farma	Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
YU183988A (en) *	1988-09-30	1990-08-31	Lek Tovarna Farmacevtskih	Process for preparing dispersion pills of dihydroergotoxine
JPH02111620A (ja) *	1988-10-21	1990-04-24	Kunimine Kogyo Kk	水中分散性粒剤
US5073377A (en) *	1988-11-03	1991-12-17	Miles Inc.	Method of preparing oral dosage forms with a granulating composition
US4965072A (en) *	1988-11-03	1990-10-23	Miles Inc.	Granulating composition and method
JPH02145501A (ja) *	1988-11-25	1990-06-05	Sanyo Chem Ind Ltd	殺生剤粒剤組成物
FI895821A0 (fi) *	1988-12-07	1989-12-05	Wellcome Found	Farmaceutiskt aktiva cns foereningar.
US4927639A (en) *	1989-02-02	1990-05-22	Warner-Lambert Company	Modified release gemfibrozil composition
US4925676A (en) *	1989-02-02	1990-05-15	Warner-Lambert Company	Extended release gemfibrozil composition
ATE107469T1 (de) *	1989-04-07	1994-07-15	Ciba Geigy Ag	Pestizide wirkstoffkonzentrate und ihre herstellung.
US4970078A (en) *	1989-05-25	1990-11-13	Aqualon Company	Crosslinked carboxymethyguar tablet disintegrant
DK0490920T3 (da) *	1989-09-07	1994-04-25	Gerhard Gergely	Mavesyrebindende farmaceutisk præparat
US5037658A (en) *	1989-09-14	1991-08-06	Hoechst-Roussel Pharmaceuticals, Inc.	Direct dry compressible acetaminophen composition
US5064656A (en) *	1989-11-14	1991-11-12	Dr. Gergely & Co.	Uncoated pharmaceutical reaction tablet
US5136080A (en) *	1989-12-04	1992-08-04	Burroughs Wellcome Co.	Nitrile compounds
JP3069665B2 (ja) *	1990-03-15	2000-07-24	住友化学工業株式会社	農業用粒状水和剤組成物
GB9012311D0 (en) *	1990-06-01	1990-07-18	Wellcome Found	Pharmacologically active cns compounds
GB9012316D0 (en) *	1990-06-01	1990-07-18	Wellcome Found	Pharmacologically active cns compounds
US5087454A (en) *	1990-07-30	1992-02-11	American Home Products Corporation	Ibuprofen tablet
GB9025372D0 (en) *	1990-11-22	1991-01-09	Nat Res Dev	Pharmaceutical dosage forms

1992
- 1992-01-29 RU RU93051524A patent/RU2106861C1/ru active
- 1992-01-29 NL NL9220009A patent/NL9220009A/nl active Search and Examination
- 1992-01-29 SK SK817-93A patent/SK282071B6/sk unknown
- 1992-01-29 CH CH309292A patent/CH685978A5/fr not_active IP Right Cessation
- 1992-01-29 WO PCT/GB1992/000163 patent/WO1992013527A1/en not_active IP Right Cessation
- 1992-01-29 HU HU9302212A patent/HU221677B1/hu unknown
- 1992-01-29 MY MYPI92000143A patent/MY110880A/en unknown
- 1992-01-29 KR KR1019930702233A patent/KR100190254B1/ko not_active IP Right Cessation
- 1992-01-29 ES ES92903508T patent/ES2089498T3/es not_active Expired - Lifetime
- 1992-01-29 FR FR9200938A patent/FR2671970B1/fr not_active Expired - Fee Related
- 1992-01-29 US US08/090,111 patent/US5556639A/en not_active Expired - Lifetime
- 1992-01-29 IE IE920284A patent/IE77165B1/en not_active IP Right Cessation
- 1992-01-29 SK SK1655-2000A patent/SK282072B6/sk unknown
- 1992-01-29 PL PL92300134A patent/PL169106B1/pl unknown
- 1992-01-29 BE BE9200088A patent/BE1004461A5/fr not_active IP Right Cessation
- 1992-01-29 IL IL10079692A patent/IL100796A/en not_active IP Right Cessation
- 1992-01-29 DE DE4290300T patent/DE4290300T1/de not_active Withdrawn
- 1992-01-29 GB GB9218097A patent/GB2257363B/en not_active Revoked
- 1992-01-29 AU AU11863/92A patent/AU653203B2/en not_active Expired
- 1992-01-29 DK DK92903508.7T patent/DK0522128T3/da active
- 1992-01-29 ES ES09250043A patent/ES2080641B1/es not_active Expired - Fee Related
- 1992-01-29 JP JP04503284A patent/JP3118255B2/ja not_active Expired - Lifetime
- 1992-01-29 AT AT92903508T patent/ATE133068T1/de not_active IP Right Cessation
- 1992-01-29 UA UA93002090A patent/UA37214C2/ru unknown
- 1992-01-29 CZ CZ19931082A patent/CZ286723B6/cs not_active IP Right Cessation
- 1992-01-29 DE DE69207656T patent/DE69207656T2/de not_active Expired - Lifetime
- 1992-01-29 EP EP92903508A patent/EP0522128B1/en not_active Expired - Lifetime
- 1992-01-29 CA CA002098108A patent/CA2098108C/en not_active Expired - Lifetime
- 1992-01-30 MX MX9200412A patent/MX9200412A/es unknown
- 1992-01-30 IT ITRM920069A patent/IT1257473B/it active IP Right Grant
- 1992-02-02 SA SA92120365A patent/SA92120365B1/ar unknown
1993
- 1993-06-22 LU LU88323A patent/LU88323A1/fr unknown
- 1993-07-02 NO NO932422A patent/NO306697B1/no not_active IP Right Cessation
- 1993-07-08 SE SE19939302363A patent/SE9302363D0/xx not_active Application Discontinuation
- 1993-07-27 DK DK93878A patent/DK87893D0/da not_active Application Discontinuation
- 1993-07-29 FI FI933401A patent/FI111605B/fi active
- 1993-08-26 BG BG098071A patent/BG61665B2/bg unknown
1994
- 1994-07-13 AU AU67454/94A patent/AU659581B2/en not_active Expired
- 1994-10-03 US US08/317,300 patent/US5660860A/en not_active Expired - Lifetime
1995
- 1995-06-28 HU HU95P/P00506P patent/HU211161A9/hu unknown
- 1995-08-24 PA PA19957695401A patent/PA7695401A1/es unknown
1996
- 1996-04-03 GR GR960400936T patent/GR3019545T3/el unknown
1997
- 1997-06-12 HK HK78597A patent/HK78597A/xx not_active IP Right Cessation
1998
- 1998-02-20 CY CY200798A patent/CY2007A/xx unknown
- 1998-02-27 MY MYPI98000866A patent/MY120025A/en unknown
2000
- 2000-03-14 JP JP2000070675A patent/JP3483515B2/ja not_active Expired - Lifetime
2002
- 2002-09-24 FI FI20021701A patent/FI20021701A/fi unknown

Also Published As

Publication number	Publication date
EP0522128B1 (en)	1996-01-17
SK81793A3 (en)	1994-03-09
NO306697B1 (no)	1999-12-13
FR2671970B1 (fr)	1995-06-23
FI933401A (fi)	1993-07-29
MY110880A (en)	1999-06-30
ITRM920069A1 (it)	1993-07-30
ES2089498T3 (es)	1996-10-01
CH685978A5 (fr)	1995-11-30
IL100796A (en)	1998-09-24
IE920284A1 (en)	1992-07-29
UA37214C2 (ru)	2001-05-15
MY120025A (en)	2005-08-30
FI933401A0 (fi)	1993-07-29
ATE133068T1 (de)	1996-02-15
HU221677B1 (hu)	2002-12-28
HUT67019A (en)	1995-01-30
FI111605B (fi)	2003-08-29
KR100190254B1 (ko)	1999-06-01
JP3118255B2 (ja)	2000-12-18
NL9220009A (nl)	1993-11-01
SK282072B6 (sk)	2001-10-08
NO932422D0 (no)	1993-07-02
RU2106861C1 (ru)	1998-03-20
PA7695401A1 (es)	1996-05-20
IT1257473B (it)	1996-01-25
MX9200412A (es)	1992-09-01
SK282071B6 (sk)	2001-10-08
KR930702959A (ko)	1993-11-29
LU88323A1 (fr)	1994-01-05
US5660860A (en)	1997-08-26
NO932422L (no)	1993-07-02
US5556639A (en)	1996-09-17
GB9218097D0 (en)	1992-11-04
EP0522128A1 (en)	1993-01-13
HK78597A (en)	1997-06-20
JPH06504544A (ja)	1994-05-26
IE77165B1 (en)	1997-12-03
DE4290300T1 (de)	1993-10-07
DK0522128T3 (da)	1996-02-26
AU6745494A (en)	1994-09-08
CZ286723B6 (cs)	2000-06-14
DE69207656D1 (de)	1996-02-29
DK87893A (da)	1993-07-27
JP3483515B2 (ja)	2004-01-06
SE9302363L (sv)	1993-07-08
JP2000273045A (ja)	2000-10-03
IL100796A0 (en)	1992-09-06
GB2257363B (en)	1994-09-28
FR2671970A1 (fr)	1992-07-31
ES2080641B1 (es)	1996-11-01
FI20021701A (fi)	2002-09-24
GB2257363A (en)	1993-01-13
PL169106B1 (pl)	1996-06-28
AU653203B2 (en)	1994-09-22
SA92120365B1 (ar)	2004-03-20
HU9302212D0 (en)	1993-10-28
GR3019545T3 (en)	1996-07-31
DK87893D0 (da)	1993-07-27
CZ108293A3 (en)	1994-01-19
ITRM920069A0 (it)	1992-01-30
BE1004461A5 (fr)	1992-11-24
ES2080641A1 (es)	1996-02-01
SE9302363D0 (sv)	1993-07-08
AU1186392A (en)	1992-09-07
WO1992013527A1 (en)	1992-08-20
CA2098108C (en)	2001-07-03
CY2007A (en)	1998-02-20
DE69207656T2 (de)	1996-10-17
CA2098108A1 (en)	1992-07-31
HU211161A9 (en)	1995-10-30
AU659581B2 (en)	1995-05-18

Publication	Publication Date	Title
BG61665B2 (bg)	1998-02-27	Вододиспергируеми таблетки
US5698226A (en)	1997-12-16	Water-dispersible tablets
US5629016A (en)	1997-05-13	Water-dispersible tablets
EP0652752B1 (en)	1999-09-15	Water-dispersible tablets
EP0685231B1 (en)	1999-07-07	Water-dispersible tablet containing lamotrigine
CA2277722C (en)	2001-03-27	Water dispersible tablets
CZ286719B6 (cs)	2000-06-14	Tablety s obsahem lamotriginu dispergovatelné ve vodě
PT101736B (pt)	1998-01-30	Comprimidos dispersiveis em agua contendo lamotrigina
NZ241441A (en)	1996-08-27	Water-dispersible tablet formulation comprising acyclovir and a swellable clay excipient
PT100197B (pt)	1998-11-30	Comprimidos dispersiveis em agua e processo para a sua preparacao